**Name :Amit Dutt, Ph.D**

**Designation :** Principal Investigator, Asst Prof./ DBT- Wellcome Fellow (Intermediate)

**Department/Institute/University** **:**ACTREC, Tata Memorial Center

**EDUCATION** (Post-Graduation onwards & Professional Career)

|  |  |  |  |
| --- | --- | --- | --- |
| **Degree** | **Year** | **Subjects** | **University** |
| B.Sc. | 1994 | Botany | Delhi University |
| P.G. Diploma | 1995 | BiochemTech | Delhi University |
| M.Sc. | 1998 | Biosciences | JMI, Central University, Delhi |
| Ph.D | 2000 | Plant Genetics | ICGEB, Delhi |
| Ph.D | 2004 | Dev. Biology | Univ of Zurich, Switzerland |

##### POSITION AND EMPLOYMENT(Starting with the most recent employment)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **InstitutionPlace** | **Position** | **From** | **To** |
| 1 | ACTREC, Tata Memorial Center, Navi  Mumbai | Principal Investigator,  Assistant Professor | Oct 22nd, 2010 | Till date |
| 2 | Broad Institute of Harvard and MIT/  Dana Farber Caner Institute, Boston, MA, USA | Research Associate | Sep 2005 | Oct 2010 |
| 3 | Institute of Molecular Life Sciences,  Zurich University, Switzerland | Graduate Student | 2001 | 2005 |
| 4 | International Center for Genetic  Engineering and Biotechnology, New Delhi | Graduate Student | 1997 | 2000 |

HONORS/AWARDS

**2011**Wellcome Trust/ DBT India Alliance Intermediate Fellowship

**2010** Ramalingaswami Fellowship Award, Department of Biotechnology, Govt of India

**2005** Awarded Swiss National Science Foundation Postdoctoral fellowship from the Govtof Switzerland, as an outstanding promising candidate.

**2004** Awarded Julius Klaus Foundation Fellowship, University of Zürich, Switzerland.

2003 Awarded complete sponsorship by The Genetics Society of America, Bethesda and a Plenary talk

1997 NET (National Eligibility Test) for CSIR-UGC JRFship and Eligibility for Lectureship

1997 NET (National Eligibility Test) jointly conducted by ASRB and (ICAR) Dec.,1997.

1997 GATE (Graduate Aptitude Test Examination)

RESEARCH GRANTS

7. Oct 2014- Sep 2016 Terry Fox Foundation grant on lung cancer, through intramural (TMC)

6.Jun 2013- May 2014 Intramural grant on RetriperitonealLiposarcomas

##### 5.Apr 2012-Mar 2014 Intramural grant on Breast Cancer.

##### 4.Oct 2012- Sep 2017 Wellcome Trust/ DBT India Alliance on head and neck cancer.

##### 3.Apr 2013-Mar 2016 Department of Biotechnology grant on genome wide pooled RNAi screen

##### 2.Oct 2011- Sep 2012 Seed-in- Air intramural grant on oral and lung cancer.

##### 1.Nov 2010- Oct 2015 Ramalingaswamy Fellowship (relinquished in Oct, 2012) on tongue cacncer

##### PUBLICATIONS

**28:** Upadhyay P, Dwivedi R,**Dutt A\***Application of NGS in Cancer Research. Current Science, 2013.*Invited Review*. (*Under review*)

**27:** Mittra I, Khare NK…. **Dutt A**. Circulating nucleic acids damage DNA of healthy cells by integrating into their genome and induce oncogenic transformation. *Under review. 2013*

**26:**Barreto SG, **Dutt A**\*, AdarshChaudhary. A Genetic Model for Gallbladder Carcinogenesis and its Dissemination.Annals of Oncology 2013 (*In Press)*

**25:**A, Prabhash K\*, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, **Dutt A**\*. Frequency of EGFR Mutations in 907 lung adenocarcioma Patients of Indian Ethnicity.*.***PLoS One.** 2013 Oct 4;8(10):e76164.

**24:**Chougule A, Prabhash K\*, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, Dutt A\*. EGFR Mutation Subtypes and Geographical Distribution Among Indian NSCLC Patients. **Indian J Cancer**. 2013 Apr-Jun;50(2):107-11.

**23:** Noronha V, Prabhash K\*, … **Dutt A**\*, Mulherkar R. EGFR Mutations in Indian Lung Cancer Patients: Clinical

Correlation and Outcome to EGFR Targeted Therapy.**PLoS One**. 2013 Apr 19;8(4):e61561

**22:** Kumar R, Horvath A… **Dutt A** et al. The Global Cancer Genomics Consortium's Second Annual Symposium :

Genomics Medicine in Cancer**. Genes & Cancer** 2013. DOI: 10.1177/1947601913484582

**21:**Eswaran J, Gupta S, **Dutt A**, et al. The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer

Medicine.Cancer Res. 2012 May 24.

**20:** Cho J, .., **Dutt A**, et alGlioblastoma-derived EGFR carboxyl-terminal deletion mutants are transforming and are

sensitive to EGFR-directed therapies.**Cancer Res**. 2011

# 19:Dutt A\* et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351\*co-corresponding author

# 18:Hammerman P, Sos ML, Ramos AH, Xu C, Dutt A et al. Mutations in the DDR2 kinase gene identify a novel

# therapeutic target in squamous cell lung cancer. Cancer Discovery 2011.

**17**: Zhou W, Hur W, McDermott U, **Dutt A**et al. A Structure-guided Approach to Creating Covalent FGFR1 Inhibitors.Chem Biol**. 2010 Mar 26;17(3):285-95**

# 16:Bass AJ, Watanabe H…Dutt A et al. SOX2 Is an Amplified Oncogene in Lung and Esophageal Squamous Cell Carcinoma. Nat Genet. 2009 Nov;41(11):1238-42.

**15**: Ramos AH\*, **Dutt A\*** et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. **Cancer BiolTher**. 2009 Nov;8(21):2042-50. \* co first authors.

**14:** Dutt A, Salvesen H, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all

members of the AKT family in endometrial carcinoma. **Br J Cancer**; 2009 Oct 6;101(7):1218-9

**13**: Salvesen HG, Cartel L, Mannelqvist M, Dutt A et al, Gene expression profiles identify an aggressive subtype of

endometrial carcinoma associated with amplification and of PIK3CA. **ProcNatlAcadSci USA**. 2009 Mar

**12**: Ding L,Gedz Gad … **Dutt** A et al. Somatic mutations affect key pathways in lung adenocarcinoma. **Nature**. 2008 Oct 23;455(7216):1069-75.

**11**: **Dutt A**, et al..Drug-sensitive FGFR2 mutations in endometrial carcinoma.**ProcNatlAcadSci U S A**. 2008 Jun 24;105(25):8713-7.

**10:** Thomas RK… **Dutt A** et al. High-throughput oncogene mutation profiling in human cancer.**Nat Genet**. 2007 Mar;39(3):347-51.

**9**: **Dutt A**, Beroukhim R. Single nucleotide polymorphism array analysis of cancer. s**CurrOpinOnco**l. 2007 Jan;19(1):43-9. Review.

**8**: **Dutt A**, Wong KK. Mouse models of lung cancer.**Clin Cancer Res**. 2006 Jul 15;12(14 Pt 2):4396s-4402s. Review.

**7**: Murtaza I… **Dutt A** et al. A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley.**World J Gastroenterol**. 2006 Jul 7;12(25):4033-7.

**6**: Murtaza I..**Dutt A**. A preliminary investigation demonstrating the effect of quercetin on the expression of genes

related to cell-cycle arrest, apoptosis and xenobiotic metabolism in human CO115 colon-adenocarcinoma cells using DNA microarray. **BiotechnolApplBiochem**. 2006 Jul;45(Pt 1):29-36.

**5**: Murtaza I, **Dutt A**, Mushtaq D, Ali A. Molecular cloning and genetic analysis of functional merB gene from indian isolates of Escherichia coli. **CurrMicrobiol**. 2005 Nov;51(5):297-302.

**4**: **Dutt A**, Canevascini S, Froehli-Hoier E, Hajnal A. EGF signal propagation during C. elegansvulval development mediated by ROM-1 rhomboid. **PLoS Biol**. 2004 Nov;2(11):e334.

**3**: Murtaza I, **Dutt A**, Ali A. Relationship between the persistence of meroperon sequences in Escherichia coli and their resistance to mercury. **CurrMicrobiol**. 2002 Mar;44(3):178-83.

**2:**Murtaza I, **Dutt A** and Ali Arif2002 Biomolecular engineering of organomercuriallyase in *Escherichia coli*. **Indian J. Biotech**. 2002;1:117-120. **(ISSN: 0972-5849)**

**1:**Murtaza I, **Dutt A**and Ali Arif. 2001 Inducible mercury operons in Broad Spectrum *Escherichia coli***Ind. J. Microbiol.** 2001; 41:169-172**, (ISSN: 0046-899)**

##### NON PUBMED/ BOOK CHAPTERS

**1:**Pratik Chandrani and **Amit Dutt** Domain specific Targeting of Cancer. Chapter XII in Book entitled, "Nuclear Signaling Pathways and Targetting Transcription in Cancer", book edited by Rakesh Kumar, published by Springer Science & Business Media

**2:**Next Generation Sequencing and Cancer Biology, by **Amit Dutt**-- an invited article in "Cutting Edge", May 2012, A Spinco Biotech Publication

##### REGULAR REVIEWER FOR

**4**. Oncogene, Clinical Cancer Research, PLOS ONE, Gene

**3.**Indian Journal of Cancer, Lung India, South Asian Journal of Cancer

**2.** BIRAC, Bangalore (Biotechnology Industry Research Assistance Council), Govt of India

**1.**Depart of Biotechnology (DBT), Govt of India—COE and Research grant reviewer

##### PROFESSIONAL CO-CURRICULAR ACTIVITIES

##### 6.Organized the DBT Sponsored Cancer Informatics Workshop on Next Gen Data Analyisfrom Jan 28-30, 2013

##### (<http://www.actrec.gov.in/pi-webpages/AmitDutt/cwi_workshop.html>)

##### 5.Organized the Second Global Cancer Genome Consortium (GCGC) TMC Symposium at ACTREC, Nov 2012—a

##### initiative by three leading academic institutions; George Washington University, USA, Oxford University, UK

##### and Tata Memorial Centre India (<http://www.gcgc.in>)

##### Organized the first Global Cancer Genome Consortium (GCGC) TMC Symposium at ACTREC, Nov 2011—a

##### initiative by hree leading academic institutions; George Washington University, USA, Oxford University, UK

##### and Tata Memorial Centre India (<http://www.gcgc.in>)

##### Organized (along with a group fellow scientsits) The Young Investigator Meeting Boston 2010 at The Broad

Institute of Harvard and MIT-- http://www. yimboston.org.

**2.**Active organizer and volunteer for the USA-India Biopharma Summit for the years 2008, 2009,2010 and for

2011- <http://www.usaindiachamber.org/current-events.shtml>

**1.**Initiated and established (along with a group of fellow graduate students) Indian Student Association of Zurich- <http://www.insaz.ethz.ch/>